John Q Walker, Ph.D., the Co-founder, and Chief Technology Officer of uMethod Health, recently participated in a distinguished panel of experts in the field of disease. The discussion centered around translating technological advancements into actionable strategies at a clinical level. Together, the panel delved into the realm of proactive, precision, and holistic medicine, identifying it as the next frontier in healthcare. Dr. Walker describes how uMethod is at the forefront…READ MORE

Michael K. Racke, MD, medical director of neurology at Quest Diagnostics, delved into some commonly-believed myths about Alzheimer disease and provided his insight on the scientific explanations for these assumptions. Common myths:#1: Only older patients need to worry about AD. #2: AD is primarily an inherited genetic disease. #3: Most patients don’t want to know if they are at risk of developing AD. #4: Only high-powered imaging tests can help evaluate for AD. #5: Only…READ MORE

Quest Diagnostics recently announced the nationwide availability of the RestoreU Dementia Panel, an artificial intelligence (AI)-based risk assessment and care service created by uMETHOD Health. In this video interview, Dr. Michael K. Racke, medical director for neurology at Quest Diagnostics, spoke to Stephen Wellman, director of content and strategy at LabPulse and The Science Advisory Board, about the challenges associated with identifying those who do not have Alzheimer's and may…READ MORE

Quest Diagnostics unveiled a new artificial intelligence-based test service in the U.S. that aims to help physicians improve the detection of dementia and create better outcomes for patients. Through a partnership with Raleigh, N.C.-based health technology company uMETHOD Health, the Secaucus-headquartered testing provider added the RestoreU Dementia Panel to its testing portfolio, according to a May 4 announcement. Dr. Michael Racke, Quest’s neurology medical director, said, “With so much attention on emerging therapies for…READ MORE

More than six million Americans are living with Alzheimer’s disease — and one in three seniors dies with the disease, according to statistics from the Alzheimer’s Association. With so many different factors — genetics, lifestyle and environment — influencing a person’s risk of developing Alzheimer’s, many doctors are moving away from one-size-fits-all approaches and calling for more individualized treatments. It’s a concept known as precision medicine. And it’s what inspired a…READ MORE

Secaucus, NJ and Raleigh, NC – May 4, 2023 – Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced nationwide availability of the RestoreU™ Dementia Panel, a risk assessment and care plan service created by uMETHOD Health, a health technology company specializing in precision medicine for chronic diseases, to help physicians close care gaps for patients with cognitive decline. The RestoreU service employs artificial intelligence…READ MORE

Quest Diagnostics and uMETHOD Health, Inc. are excited to announce the national launch of a robust solution in the fight against dementia. Using a 3-step approach that combines our advanced testing with uMETHOD’s AI-based technology, you can help patients prevent cognitive decline, improve brain health, and maintain independence. Learn more about Quest Diagnostic's Alzheimer's disease testing portfolio at Questforthecure.com or contact a uMETHOD Health representative today.…READ MORE

World Kidney Day has been observed in early March since 2006;  in the US, March is National Kidney Month. Efforts to increase awareness of kidney health are timely, as chronic kidney disease (CKD) affected an estimated 37 million Americans in 2021. Drugs prescribed for common illnesses can increase the risk or severity of CKD. This risk comes in addition to drug-to-drug interactions (DDIs) that might also exacerbate CKD. And unfortunately,…READ MORE

uMETHOD Health is partnering with regional and national diagnostic laboratories and hundreds of physicians to identify and address the multiple factors that contribute to cognitive issues in seniors. The Raleigh, NC-based company produces leading-edge medical artificial intelligence (AI) and services to target complex diseases such as Alzheimer’s Disease (AD). On the 29th annual World Alzheimer’s Day, uMETHOD states there are multiple contributors involved in the progression of AD and they…READ MORE

uMETHOD is excited to announce the release of its breakthrough methodology -- called ExtND METHOD -- designed to finally provide a prevention solution to the over 70 million women and men in the USA at risk of Alzheimer’s disease and cognitive decline. The complexity of treating and preventing cognitive decline due to dozens of biological mechanisms and hundreds of interventions is now made straightforward through the application of uMETHOD’s proprietary…READ MORE